Bioinfra Life Science

Bioinfra Life Science is a South Korean global healthcare company established in 2001 at Seoul National University's Samsung Cancer Research Center, focused on developing innovative in-vitro cancer screening diagnostics and targeted anticancer therapies. The company has developed a blood-based multi-marker test capable of analyzing the risk of eight major cancers — including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer — using just a small blood sample, based on more than 15 years of oncology research. Bioinfra Life Science also develops cancer gene treatments and technologies for monitoring metastasis and recurrence, with operations spanning diagnostics, therapeutics, and research in Seoul.